ADMA Biologics, Inc. Quarterly report pursuant to Section 13 or 15(d)

12. SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Details) - USD ($)	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
SUPPLEMENTAL INFORMATION:
Cash paid for interest	$ 1,217,524	$ 1,104,417
Noncash Financing and Inesting Activities:
Assets acquired through the issuance of common stock and liabilities assumed	60,161,629	0
Equipment acquired reflected in accounts payable and accrued liabilities	1,363,563	0
End of term liability for Oxford Note Payable	0	358,000
Warrants issued in connection with note payable	$ 0	$ 86,300